The early interaction procedures with regulatory authorities established to support the development of innovative medicines can be divided into the following three categories:
- Support mechanisms established by the European Medicines Agency (EMA) at European Union level. Please see: Support for innovative medicines’ development at the EMA level.
- Support mechanisms involving several competent authorities, such as the EMA and the Food and Drug Administration (FDA), several national medicines agencies, or several health technology assessment bodies within the European Union. Please see: Support from several competent authorities for the development of innovative medicines.
- Support mechanisms established by national medicines agencies at the national levels within the European Union. Please see: Support from National medicines Agencies for the development of innovative medicines at the National levels.